Asia
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope.
Biopharma companies from across the globe provide updates to their business operations and pipelines.
The United States leads the world in biotech innovation, but does it also lead the world in the development of COVID-19 diagnostics, vaccines and therapeutics?
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
Takeda Pharmaceutical and a subsidiary of Germany-based Evotec SE forged a long-term research collaboration that will support the Japanese company’s growing number of research stage gene therapy discovery programs.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
PRESS RELEASES